AXGN:NASDAQ
AxoGen, Inc Common Stock
51,35 USD
0,00%
(0,00) 1D
4-ноя., 16:00:01 GMT-5 · USD
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for AXGN...
Mkt. cap
3,07 млд
Avg. vol.
1,78 млн
Volume
25,00
52-wk high
52,91 USD
52-wk low
23,00 USD
EPS
-0,68 USD
Beta
1,21
Shares outstanding
59,73 млн
No. of employees
622
Mkt. cap
3,07 млд
Avg. vol.
1,78 млн
Volume
25,00
52-wk high
52,91 USD
52-wk low
23,00 USD
EPS
-0,68 USD
Beta
1,21
Shares outstanding
59,73 млн
No. of employees
622
News stories
From web sources and news partners
www.marketscreener.com
·
31 мүнөт мурун
Primech Holdings (Nasdaq: PMEC) Secures Approximately US$1.67 Million in Cleaning Services Contracts Running to 2029 Across Singapore’s Industrial and Residential Sectors
Yahoo! Finance Canada
·
21 мүнөт мурун
NYSE Chair Sharon Bowen Earns Lifetime Achievement Award: NYSE Content Update
FinancialContent
·
38 мүнөт мурун
CRA (NASDAQ:CRAI) reports strong Q3 2026, full-year sales guidance is optimistic
Seeking Alpha
·
14 мүнөт мурун
S&P 500 Outlook: The 2027 Rally Depends On 2028 Earnings (SP500)
Profile
Axogen is a developer of surgical solutions, including human tissue grafts, based in Tampa, Florida. Axogen products are designed to remedy peripheral nerve damage. In 2013 the company raised $18 million in its initial public offering. Axogen uses a cell graft technology Avance to mimic a human nerve. The company also creates nerve connectors and soft tissue membranes. The company reports sensory and movement recovery in 87 percent of patients with peripheral nerve injuries. Axogen is part of the Sid Martin Biotechnology Incubator.
As of 2019, Axogen was the only commercially available nerve allograft approved by the Food and Drug Administration for clinical use. Wikipedia
About AxoGen, Inc Common Stock
CEO-
Employees622
Founded2002
HeadquartersАлачуа, Флорида, Америка Кошмо Штаттары
SectorMedical device
Industry-
Websiteaxogeninc.com